17-Apr-2026
No headlines found.
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Tue, 31-Mar 4:05 PM ET)
Globe Newswire (Tue, 24-Mar 4:05 PM ET)
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer
Globe Newswire (Mon, 23-Mar 8:05 AM ET)
MaxCyte unveils ExPERT DTx , a 96-well electroporation platform to accelerate discovery
Globe Newswire (Tue, 24-Feb 8:05 AM ET)
MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026
Globe Newswire (Mon, 23-Feb 4:05 PM ET)
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
Maxcyte trades on the NASDAQ stock market under the symbol MXCT.
As of April 17, 2026, MXCT stock price climbed to $0.85 with 524,897 million shares trading.
MXCT has a beta of 1.56, meaning it tends to be more sensitive to market movements. MXCT has a correlation of 0.10 to the broad based SPY ETF.
MXCT has a market cap of $90.60 million. This is considered a Micro Cap stock.
Last quarter Maxcyte reported $7 million in Revenue and -$.09 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.01.
In the last 3 years, MXCT traded as high as $5.55 and as low as $.64.
The top ETF exchange traded funds that MXCT belongs to (by Net Assets): IWM, VTI, VXF, IWN, VTWO.
MXCT has underperformed the market in the last year with a return of -67.5%, while the SPY ETF gained +36.3%. In the last 3 month period, MXCT fell short of the market, returning -32.7%, while SPY returned +2.9%. However, in the most recent 2 weeks MXCT has outperformed the stock market by returning +13.1%, while SPY returned +8.3%.
MXCT support price is $.78 and resistance is $.85 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MXCT shares will trade within this expected range on the day.